Genetics, Neurology, Behavior, and Diet in Parkinson's Disease

<p>Part I: Genetics, molecular and cellular biology</p> <p>2. Alpha-synuclein gene and Parkinson’s diseaseAthina-Maria Simitsi, Chistos Koros and Leonidas Stefanis</p> <p>3. The DJ-1 gene and protein: links with Parkinson’s diseaseVanessa J. Musco, Sarah J. Annesley and Paul R. Fisher</p> <p>4. Regulation of tyrosine hydroxylase: relevance to Parkinson’s diseaseGelareh Alam and Jason R. Richardson</p> <p>5. Linking glucocerebrosidase gene (GBA) variants and Parkinson’s diseasectoria Berge-Seidl and Mathias Toft</p> <p>6. Astrocytes and microglia in Parkinson’s disease and animal modelsKatarzyna Kuter</p> <p>7. The role of autophagy in Parkinson’s disease etiopathogenesisEmanuel Candeias, Jãao Duarte Magalhães, Daniel Santos, Helena Costa, Diana F. Silva, Ana Raquel Esteves and Sandra Morais Cardoso</p> <p>8. The mitochondrial network in Parkinson’s diseaseAndreas Aufschnaiter, Verena Kohler and Sabrina Büttner</p> <p>9. Signal transduction in Parkinson’s disease: modulation of neurotransmission, symptomatology, and therapyMattia Volta</p> <p>10. Oxidative stress signaling and regulated cell death in Parkinson’s diseaseCarlos Velez-Pardo and Marlene Jimenez-Del-Rio</p> <p>11. Subcellular-specific alpha-synuclein in Parkinson’s diseaseBenjamin Rosen, Ketan S. Patil, Guido W. Alves and Simon G. Møller</p> <p>12. Melanocortin 1 receptor: Parkinson’s disease, melanoma risk, and neuroprotectionGemma Tell-Marti, Joan Anton Puig-Butillé and Susana Puig</p> <p>13. Energy regulation and Parkinson’s diseaseLiting Hang and Kah-Leong Lim</p> <p>14. Linking rotigotine, Parkinson’s disease, and brain-derived neurotrophic factorKazuhiro Sohya, Kazunori O’Hashi and Hiroshi Kunugi</p> <p>Part II: Neurology, physiology and imaging</p> <p>15. The different syndromes in Parkinson’s disease: an overviewNikolaos Giagkou and Maria Stamelou</p> <p>16. Neuromolecular imaging in Parkinson’s diseasePatricia A. Broderick and Leslie Wenning</p> <p>17. Interlinking brain mapping and Parkinson’s disease: MRI analysis, nigrosome 1 and nigrosome 4Eung Yeop Kim, Young Hee Sung and Jongho Lee</p> <p>18. Interconnecting Parkinson’s disease: the use of computed tomography and microelectrode recording in DBS surgeryRyan B. Kochanski and Sepehr Sani</p> <p>19. Linking diffusion tensor imaging, microstructures and Parkinson’s diseaseYu Zhang, Norbert Schuff, I-Wei Wu and Duygu Tosun</p> <p>20. Detecting parkinsonian degeneration in lateroventral tier of substantia nigra pars compacta with MRIJason Langley, Daniel E. Huddleston and Xiaoping P. Hu</p> <p>21. Vagal motoneurons in Parkinson’s diseaseRuth E. Musgrove, Wei-Hua Chiu and Joshua A. Goldberg</p> <p>22. Circadian clock disruption and neuroinflammation in Parkinson’s disease: a new perspective Elisabetta Lauretti and Domenico Praticò</p> <p>23. Motor cortex stimulation in Parkinson’s diseaseAngelo Lavano, Giusy Guzzi, Attilio Della Torre and Domenico La Torre</p> <p>24. Action programming disorders associated with Parkinson’s diseaseKenneth M. Heilman</p> <p>25. The striatal medium spiny neurons: what they are and how they link with Parkinson’s diseaseFu-Ming Zhou</p> <p>26. Disruptions of frontostriatal language functions in Parkinson’s diseaseAdolfo M. García, Yamile Bocanegra, Agustina Birba, Juan Rafael Orozco-Arroyave, Lucas Sedeño and Agustín Ibañez</p> <p>27. Alpha-synuclein and neuroinflammation in Parkinson’s diseaseTatiana Varanita and Luigi Bubacco</p> <p>28. Tau and its interactions with other proteins in neurodegenerative diseasesKatelyn H. Mroczek, Sarah J. Annesley and Paul R. Fisher</p> <p>29. Interaction between brain angiotensin and dopaminergic systems and Parkinson’s diseaseJose Luis Labandeira-Garcia, Pablo Garrido-Gil, Maria A. Pedrosa, Carmen M. Labandeira and Ana I. Rodriguez-Perez</p> <p>30. Restoring dopamine levels in Parkinson’s disease: neuronal pathways, agonists and antiinflammatory agentsÁgatha Oliveira-Giacomelli, C.M. Albino, Hellio Danny Nóbrega de Souza and Henning Ulrich</p> <p>Part III: Behaviour and psychopathology </p> <p>31. Motivation and motivational aspects of Parkinson’s diseaseAbdeslam Chagraoui, Emilie Puginier and Philippe De Deurwaerdère</p> <p>32. Linking anxiety, cognitive and sensory deficits to gait and balance deficits in Parkinson’s diseaseQuincy J. Almeida</p> <p>33. Motor programs interlinking gait and bradykinesia in Parkinson’s diseaseTateo Warabi, Kiyoharu Inoue and Nobuo Yanagisawa</p> <p>34. Olfactory disturbances in Parkinson’s diseaseLais S. Rodrigues, Juliane Fagotti, Adriano D.S. Targa, Ana Carolina D. Noseda, Jessica L. Ilkiw, Flavia W.C. Dorieux and Marcelo M.S. Lima</p> <p>35. Interlinking dementia in Parkinson’s disease: nutritional correlates of body compositionArthur Oscar Schelp, Jéssica Emy Komuro, José Eduardo Corrente and Silvia Justina Papini</p> <p>36. The role of the gastrointestinal system and gut microbiota in Parkinson’s diseaseJade Kenna and Ryan S. Anderton</p> <p>37. Swallowing impairment in Parkinson’s diseaseMaira Rozenfeld Olchik, Marina Padovani and Annelise Ayres</p> <p>38. The Mini Nutritional Assessment (MNA) and applications to Parkinson’s diseaseSvetlana Tomic</p> <p>39. The efficacy of Bacopa monnieri extract in modulating Parkinson’s diseaseDr. Ravikumar Hosamani</p> <p>Part V: Models, modelling and resources</p> <p>40. 6-hydroxydopamine-induced model of Parkinson’s diseaseKatarzyna Kaczyńska and Kryspin Andrzejewski</p> <p>41. Knockdown transgenic Drosophila and Parkinson’s diseaseMarlene Jimenez-Del-Rio and Carlos Velez-Pardo</p> <p>42. Neuroprotection in animal models of Parkinson’s disease: exploring exercise, sound, and lightJohn Mitrofanis</p> <p>43. Modeling with the A53T α-synuclein model of Parkinson’s diseaseThomas Musacchio, James B. Koprich and Chi Wang Ip</p> <p>44. Linking the leucine-rich repeat kinase 2 gene, animal models, and Parkinson’s diseaseYulan Xiong and Jianzhong Yu</p> <p>45. Neuroscience of Parkinson’s disease: recommended reading and resourcesRajkumar Rajendram, Vinood B. Patel and Victor R. Preedy</p>